Synopsis

Source of validity: Scientific
Rating (out of 5): 5

Ethyl esters of omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are well-supported by scientific evidence for the treatment of high triglycerides (hypertriglyceridemia). Prescription omega-3 ethyl esters, such as Lovaza (formerly Omacor), contain concentrated EPA and DHA in ethyl ester form and have been extensively studied in randomized controlled trials. Meta-analyses and clinical guidelines from organizations like the American Heart Association and National Lipid Association recognize their efficacy.

Clinical trials consistently demonstrate that high-dose omega-3 ethyl esters (typically 2-4 grams per day) can lower triglyceride levels by 20-50% in adults with elevated triglycerides. The mechanism is believed to involve reduced hepatic VLDL (very-low-density lipoprotein) synthesis and increased clearance of triglyceride-rich particles. The FDA has approved prescription omega-3 ethyl esters for the treatment of severe hypertriglyceridemia (≥500 mg/dL).

It is important to note that while omega-3 ethyl esters effectively lower triglycerides, their impact on cardiovascular outcomes is less clear and may depend on the specific formulation and patient population. Nevertheless, for the specific indication of lowering high triglycerides, ethyl ester forms of omega-3s are backed by robust scientific validation.

More about Ethyl Esters (unspecified)
More about Triglycerides (high)

Other ingredients used for Triglycerides (high)

Other health conditions supported by Ethyl Esters (unspecified)

Products containing Ethyl Esters (unspecified)